Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes)

J Am Coll Cardiol. 2013 Apr 30;61(17):1767-76. doi: 10.1016/j.jacc.2013.01.062. Epub 2013 Feb 28.

Abstract

Objectives: This study evaluated differences in outcome among women and men enrolled in the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial.

Background: Women and men with coronary artery disease have different clinical presentations and outcomes that might be due to differences in management.

Methods: We compared baseline variables, study interventions, and outcomes between women and men enrolled in the BARI 2D trial and randomized to aggressive medical therapy alone or aggressive medical therapy with prompt revascularization.

Results: At enrollment, women were more likely than men to have angina (67% vs. 58%, p < 0.01) despite less disease on angiography (Myocardial Jeopardy Index 41 ± 24 vs. 46 ± 24, p < 0.01; number of significant lesions 2.3 ± 1.7 vs. 2.8 ± 1.8, p < 0.01). Over 5 years, no sex differences were observed in BARI 2D study outcomes after adjustment for difference in baseline variables (death/myocardial infarction/cerebrovascular accident: hazard ratio: 1.11, 99% confidence interval [CI]: 0.85 to 1.44). However, women reported more angina than men (adjusted odds ratio: 1.51, 99% CI: 1.21 to 1.89, p < 0.0001) and had lower scores for the Duke Activity Status Index (adjusted beta coefficient: -1.58, 99% CI: -2.84 to -0.32, p < 0.01).

Conclusions: There were no sex differences in death, myocardial infarction, or cerebrovascular accident among patients enrolled in the BARI 2D trial. However, compared with men, women had more symptoms and less anatomic disease at baseline, with persistence of higher angina rates and lower DASI scores after 5 years of medical therapy with or without prompt revascularization. (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes [BARI 2D]; NCT00006305).

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage
  • Adult
  • Aged
  • Angina Pectoris / epidemiology*
  • Angina Pectoris / etiology
  • Angioplasty, Balloon, Coronary*
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Calcium Channel Blockers / administration & dosage
  • Cardiovascular Agents / therapeutic use*
  • Coronary Artery Bypass* / methods
  • Coronary Artery Disease / complications
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / surgery
  • Coronary Artery Disease / therapy*
  • Diabetes Complications / therapy
  • Diabetes Mellitus, Type 2 / complications*
  • Diet
  • Diuretics / administration & dosage
  • Exercise
  • Female
  • Follow-Up Studies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage
  • Prevalence
  • Quality of Life
  • Risk Reduction Behavior*
  • Severity of Illness Index
  • Sex Distribution
  • Sex Factors
  • Smoking Cessation
  • Social Support
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Calcium Channel Blockers
  • Cardiovascular Agents
  • Diuretics
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors

Associated data

  • ClinicalTrials.gov/NCT00006305